Mexidol 125mg coated film pills N30
Condition: New product
986 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Ethyl methyl hydroxypyridine succinate
Release form
Pills
Composition
Active ingredient: Ethylmethylhydroxypyridine succinate (Ethylmethylhydroxypyridine succinate) Active ingredient concentration (mg): 125
Pharmacological effect
Antioxidant drug. Mexidol is an inhibitor of free radical processes, a membrane protector with antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The drug increases the body's resistance to the effects of various damaging factors (shock, hypoxia and ischemia, cerebral circulation disorders, alcohol intoxication and antipsychotics / neuroleptics /). The mechanism of action of the drug Mexidol is due to its antioxidant, antihypoxic and membrane-protective action. The drug inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the ratio of lipid-protein, reduces the viscosity of the membrane, increases its fluidity. Mexidol modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, contributes to preserving the structural and functional organization of biomembart, and using the same patterns; Mexidol increases the content of dopamine in the brain. It causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in ATP and creatine phosphate, activation of energy-synthesizing functions of mitochondria, stabilization of cell membranes. The drug improves the metabolism and blood supply of the brain, improves microcirculation and rheologic blood of the blood, improves the metabolism and blood flow of the brain, improves microcirculation and rheologic blood of the blood. platelet aggregation. Stabilizes membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and LDL. The antistress effect is manifested in the normalization of post-stress behavior, somato-vegetative disorders, restoration of sleep-wake cycles, impaired learning processes and memory, reducing dystrophic and morphological changes in various brain structures. Mexidol has a pronounced antitoxic action with withdrawal syndrome.Eliminates neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disorders, autonomic functions, and is also able to relieve cognitive impairment caused by prolonged use of ethanol and its abolition. Under the influence of Mexidol, the effect of tranquilizing, neuroleptic, anti-depressive, hypnotic and anticonvulsant drugs is enhanced, which allows to reduce their doses and reduce side effects. Mexidol improves the functional state of the ischemic myocardium. Under conditions of coronary insufficiency, it increases the collateral blood supply to the ischemic myocardium, helps to preserve the integrity of the cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility with reversible cardiac dysfunction.
Pharmacokinetics
Absorption and distributionQuickly absorbed when taken orally. Cmax at doses of 400-500 mg is 3.5-4.0 mcg / ml. It is rapidly distributed in organs and tissues. The average retention time of the drug in the body when administered orally is 4.9-5.2 hours. Metabolism Metabolized in the liver by glucuron conjugation. Five metabolites have been identified: 3-hydroxypyridine phosphate - formed in the liver and, with the participation of alkaline phosphatase, decomposes into phosphoric acid and 3-hydroxypyridine; The 2nd metabolite is pharmacologically active, it is formed in large quantities and is found in the urine for 1-2 days after administration; 3rd - is excreted in large quantities with urine; The 4th and 5th are glucuronoconjugates. Excretion of T1 / 2 by ingestion is 2-2.6 hours. It is rapidly excreted in the urine mainly in the form of metabolites and in an insignificant amount - unchanged. Most intensively displayed during the first 4 hours after taking the drug. Indicators of urinary excretion of unchanged drug and metabolites have individual variability.
Indications
Consequences of acute disorders of cerebral circulation, incl. after transient ischemic attacks, in the phase of subcompensation (as prophylactic courses); - mild traumatic brain injury, effects of craniocerebral injuries; - encephalopathy of various genesis (dyscirculatory, dysmetabolic, post-traumatic, mixed); - vegetative dystonia syndrome; - mild cognitive disorders of atherosclerotic genesis; - anxiety disorders in neurotic and neurosis-like states; - IHD (as part of complex therapy); - relief of withdrawal syndrome in alcoholism with a prevalence of m neurosis and vegetative-vascular disorders,postabstinent disorders; - conditions after acute intoxication with antipsychotics; - asthenic conditions, as well as to prevent the development of somatic diseases under the influence of extreme factors and exercise; - exposure to extreme (stress) factors.
Contraindications
Acute liver failure; - Acute renal failure; - Hypersensitivity to the drug. Due to insufficient study of the drug's action: - Childhood; - Pregnancy; - Lactation (breastfeeding).
Precautionary measures
Do not exceed recommended doses.
Use during pregnancy and lactation
Mexidol is contraindicated during pregnancy and lactation (breastfeeding) due to insufficient knowledge of the drug.
Dosage and administration
Inside 125-250 mg 3 times / day; the maximum daily dose is 800 mg (6 tab.). The duration of treatment is 2-6 weeks; for stopping alcohol withdrawal - 5-7 days. Treatment is stopped gradually, reducing the dose within 2-3 days. The initial dose is 125-250 mg (1-2 tab.) 1-2 times / day with a gradual increase to obtain a therapeutic effect; the maximum daily dose is 800 mg (6 tab.). The duration of the course of therapy in patients with coronary artery disease is at least 1.5-2 months. Repeated courses (as recommended by the doctor) are preferably carried out in the spring and autumn periods.
Side effects
On the part of the digestive system: the appearance of individual adverse reactions may be dyspeptic or dyspeptic. Other: possible allergic reactions.
Overdose
Overdose may cause drowsiness.
Interaction with other drugs
Mexidol can be combined with all drugs used to treat somatic diseases. When combined, Mexidol enhances the effect of benzodiazepine derivatives, antidepressants, anxiolytics, antiparkinsonian and anticonvulsant drugs. Mexidol reduces the toxic effect of ethyl alcohol.
special instructions
Impact on the ability to drive motor vehicles and control mechanisms. During the period of treatment, care must be taken when driving motor vehicles and engaging in other potentially hazardous activities that require increased concentration and psychomotor reactions.